Telomir Pharmaceuticals, Inc. (TELO) stock
TELONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.42−0.06 (-12.04%)
Close on Nov 17, 2026Market cap $29.10MP/E –Yield –
Telomir Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Telomir Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$4.57M. For fiscal 2025 it was -$3.69M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.69M | – |
| FY2024 | Dec 31, 2024 | -$5.07M | – |
| FY2023 | Dec 31, 2023 | -$3.86M | – |
| FY2022 | Dec 31, 2022 | -$468.66K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$586.44K | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.01M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.77M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$927.26K | – |
| Q2 FY2025 | Jun 30, 2025 | -$696.45K | – |
| Q1 FY2025 | Mar 31, 2025 | -$863.13K | – |
| Q4 FY2024 | Dec 31, 2024 | -$605.81K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.52M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.94M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.09M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.00M | – |
| Q2 FY2023 | Jun 30, 2023 | -$33.58K | – |
| Q1 FY2023 | Mar 31, 2023 | -$735.74K | – |
See a number that looks wrong?